Dauntless Investment Group LLC Purchases New Stake in Novavax, Inc. (NASDAQ:NVAX)

Dauntless Investment Group LLC purchased a new position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 86,861 shares of the biopharmaceutical company's stock, valued at approximately $698,000. Novavax comprises 0.7% of Dauntless Investment Group LLC's investment portfolio, making the stock its 10th largest holding. Dauntless Investment Group LLC owned 0.05% of Novavax at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Franklin Resources Inc. grew its stake in Novavax by 300.4% in the 3rd quarter. Franklin Resources Inc. now owns 97,162 shares of the biopharmaceutical company's stock valued at $1,226,000 after buying an additional 72,894 shares in the last quarter. Shah Capital Management boosted its holdings in shares of Novavax by 13.6% in the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company's stock worth $89,637,000 after acquiring an additional 1,333,305 shares during the period. Arizona State Retirement System grew its position in shares of Novavax by 14.9% in the fourth quarter. Arizona State Retirement System now owns 41,793 shares of the biopharmaceutical company's stock valued at $336,000 after purchasing an additional 5,407 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Novavax by 0.4% during the 4th quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company's stock valued at $3,509,000 after purchasing an additional 1,664 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Novavax by 6.7% during the 4th quarter. Rhumbline Advisers now owns 208,464 shares of the biopharmaceutical company's stock worth $1,676,000 after purchasing an additional 13,024 shares in the last quarter. Institutional investors own 53.04% of the company's stock.

Novavax Trading Down 3.4 %

Shares of NASDAQ:NVAX traded down $0.23 during trading on Tuesday, reaching $6.49. The company had a trading volume of 2,069,715 shares, compared to its average volume of 8,334,775. The company has a fifty day moving average of $7.10 and a two-hundred day moving average of $8.28. The stock has a market capitalization of $1.04 billion, a P/E ratio of -2.87, a price-to-earnings-growth ratio of 2.85 and a beta of 3.15. Novavax, Inc. has a 12 month low of $4.10 and a 12 month high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to the consensus estimate of $85.48 million. During the same quarter last year, the company posted ($1.44) earnings per share. As a group, equities research analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on NVAX. TD Cowen upgraded Novavax to a "hold" rating in a research report on Thursday, February 27th. BTIG Research began coverage on shares of Novavax in a report on Friday, February 28th. They set a "buy" rating and a $19.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $18.00.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.